COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Total Intravenous Anesthesia (TIVA) vs. Inhaled Anesthesia for Endoscopic Sinus Surgery.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01214057
Recruitment Status : Terminated (the study was terminated for patient recruitment difficulty and interim power analysis)
First Posted : October 4, 2010
Last Update Posted : May 20, 2013
Information provided by (Responsible Party):
Davide Cattano, The University of Texas Health Science Center, Houston

Brief Summary:
The purpose of this study is to compare total intravenous anesthesia to inhaled anesthesia in endoscopic sinus surgery for chronic sinusitis. The investigators will compare bleeding during surgery, duration of surgery, blood flow to the nose and other parameters. The investigators hypothesize that total intravenous anesthesia decreases bleeding and improves the view during surgery.

Condition or disease Intervention/treatment Phase
Chronic Rhinosinusitis. Drug: Propofol and Remifentanyl Drug: Sevoflurane and Remifentanyl Not Applicable

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 23 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Preliminary Study to Assess the Effects of Total Intravenous Anesthesia With Propofol/Remifentanyl Compared to Sevoflurane/Remifentanyl for Endoscopic Sinus Surgery: Novel Approach.
Study Start Date : May 2010
Actual Primary Completion Date : October 2012
Actual Study Completion Date : October 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Endoscopy

Arm Intervention/treatment
Experimental: Total Intravenous Anesthesia
Total Intravenous Anesthesia (TIVA) with propofol and remifentanyl
Drug: Propofol and Remifentanyl
Anesthesia will be induced with lidocaine 0.5 mg kg, propofol infusion at 250 mcg/kg/min (to reduce visual bias of propofol infusion) and total volume infused will be adjusted for an induction dose of 2-3 mg/kg before bolus of muscle relaxant, rocuronium 0.5 mg kg in both SR and PR groups. Remifentanil infusion will be started at a rate of 0.4 mcg/kg/min 1-2 minutes before the propofol infusion and a 100 ml 0.9% normal saline bag will be used to blind surgeons in the sevoflurane group. The target mean arterial blood pressure (MAP) will be maintained at 70-80 mm Hg by adjusting the propofol concentration within their range (100-150 mg ml for propofol) according to the anaesthesiologist's judgement and by surgeon request. If this failed, the remifentanil rate will be adjusted by 0.05 mg kg min.
Other Names:
  • Propofol brand name is Diprivan
  • Remifentanyl brand name is Ultiva

Active Comparator: Inhaled Anesthesia
Inhaled anesthesia with sevoflurane and remifentanyl.
Drug: Sevoflurane and Remifentanyl
Sevoflurane 1-3% will be administered in group SR, and the infusion of propofol will be stopped. After intubation remifentanil infusion will be changed to 0.2 mcg/kg/min. The target mean arterial blood pressure (MAP) will be maintained at 70-80 mm Hg by adjusting the sevoflurane concentration within their range (between 1-3 vol% for sevoflurane) according to the anaesthesiologist's judgement and by surgeon request.If this failed, the remifentanil rate will be adjusted by 0.05 mg kg min.In order to limit the amount of fluids remifentanil wil be diluted at a concentration of 4 mg in 100 ml.
Other Names:
  • Remifentanyl brand name is Ultiva
  • Sevoflurane brand name is Ultane and Sojourn

Primary Outcome Measures :
  1. Bleeding [ Time Frame: upto 1 day ]
    Blood loss will be measured by counting the volume in the collection canisters and substracting the volume of irrigation used intraoperatively. The Neptune Waste Management System will be used for this purpose. This is a closed suction system that digitally counts the amount of fluid suctioned.

  2. Surgical Field Visualization [ Time Frame: upto 1 day ]
    The surgical grade score will be based on the Boezaart surgical risk assessment score. This is an inexpensive, reliable, and sensitive tool to rapidly evaluate intraoperative bleeding in ESS. The score of the operative field will be compared between the groups.

  3. Assess platelet function [ Time Frame: upto 1 day ]
    Thromboelastography-Platelet Mapping will be performed on each patient and the results will be compared between the groups. The test will be performed before induction and in the PACU. This will determine baseline platelet function, the effect of the anesthetics.

  4. Assess nasal blood flow to the sinonasal mucosa [ Time Frame: upto 1 day ]
    The Rhinolux will determine differences in the nasal blood flow between groups after induction of anesthesia, in a continous fashion. The Rhinolux is designed to measure changes in the swelling of the nasal mucosa by a tissue light absorption technique similar to that used in pulse oximetry.

Secondary Outcome Measures :
  1. Comparison of operative time [ Time Frame: The day of surgery ]
    Operative time will be measured and compared between the 2 groups.

  2. Comparison of quality of recovery. [ Time Frame: The day of surgery ]
    Patients will be asked regarding nausea and pain in the recovery unit. One microgram of fentanyl/kg and/or 0.05 mg of morphine would be given if the patient's numeric rating scale (NRS) of pain is more than 6 before leaving the OR. In the PACU Morphine 1-2 mg IV bolus every 5-10 minutes will be provided as well as ondansetron 4 mg IV bolus. Alternative medications and or supplements will be provided and noted if necessary.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Clinical diagnosis of chronic rhinosinusitis
  • Indication by the surgeon of need for endoscopic sinus surgery

Exclusion Criteria:

  • Pregnancy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01214057

Layout table for location information
United States, Texas
Memorial Hermann Hospital - Medical Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
The University of Texas Health Science Center, Houston
Layout table for investigator information
Principal Investigator: Davide Cattano, MD PhD The University of Texas Health Science Center, Houston
Layout table for additonal information
Responsible Party: Davide Cattano, Associate Professor - Anesthesiology, The University of Texas Health Science Center, Houston Identifier: NCT01214057    
Other Study ID Numbers: HSC-MS-10-0014
First Posted: October 4, 2010    Key Record Dates
Last Update Posted: May 20, 2013
Last Verified: May 2013
Keywords provided by Davide Cattano, The University of Texas Health Science Center, Houston:
chronic rhinosinusitis
endoscopic sinus surgery
surgical field visualization
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypnotics and Sedatives
Central Nervous System Depressants
Physiological Effects of Drugs
Anesthetics, Intravenous
Anesthetics, General
Platelet Aggregation Inhibitors
Anesthetics, Inhalation
Analgesics, Opioid
Sensory System Agents
Peripheral Nervous System Agents